JP7700043B2 - Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 - Google Patents

Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 Download PDF

Info

Publication number
JP7700043B2
JP7700043B2 JP2021557941A JP2021557941A JP7700043B2 JP 7700043 B2 JP7700043 B2 JP 7700043B2 JP 2021557941 A JP2021557941 A JP 2021557941A JP 2021557941 A JP2021557941 A JP 2021557941A JP 7700043 B2 JP7700043 B2 JP 7700043B2
Authority
JP
Japan
Prior art keywords
cancer
her2
mutations
poziotinib
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527499A5 (cg-RX-API-DMAC7.html
JP2022527499A (ja
Inventor
ジャクリーン ロビショー
ジョン ブイ. ヘイマック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2022527499A publication Critical patent/JP2022527499A/ja
Publication of JP2022527499A5 publication Critical patent/JP2022527499A5/ja
Application granted granted Critical
Publication of JP7700043B2 publication Critical patent/JP7700043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021557941A 2019-03-29 2020-03-27 Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 Active JP7700043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826758P 2019-03-29 2019-03-29
US62/826,758 2019-03-29
PCT/US2020/025478 WO2020205632A1 (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Publications (3)

Publication Number Publication Date
JP2022527499A JP2022527499A (ja) 2022-06-02
JP2022527499A5 JP2022527499A5 (cg-RX-API-DMAC7.html) 2023-03-30
JP7700043B2 true JP7700043B2 (ja) 2025-06-30

Family

ID=72666271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557941A Active JP7700043B2 (ja) 2019-03-29 2020-03-27 Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物

Country Status (13)

Country Link
US (1) US12629375B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946632A4 (cg-RX-API-DMAC7.html)
JP (1) JP7700043B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210145161A (cg-RX-API-DMAC7.html)
CN (1) CN113766955A (cg-RX-API-DMAC7.html)
AU (1) AU2020256119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019376A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132834A1 (cg-RX-API-DMAC7.html)
IL (1) IL286576A (cg-RX-API-DMAC7.html)
MX (1) MX2021011925A (cg-RX-API-DMAC7.html)
PH (1) PH12021552110A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109531UA (cg-RX-API-DMAC7.html)
WO (1) WO2020205632A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
JP7709384B2 (ja) * 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
UY39593A (es) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos
EP4568994A1 (en) * 2022-08-09 2025-06-18 Heligenics, Inc. Method for evaluating clinical relevance of genetic variance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516082A (ja) 2011-06-07 2014-07-07 ハンミ ファーム. シーオー., エルティーディー. ガン細胞の増殖を阻害するアミド誘導体および非金属塩滑沢剤を含む医薬組成物
WO2017210214A1 (en) 2016-05-31 2017-12-07 Pierian Holdings, Inc. Methods of drug therapy selection for breast cancer patients based on her2 and her3 pathway subtyping

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
MX2007009265A (es) 2005-02-04 2007-09-07 Boehringer Ingelheim Int Uso de inhibidores de tirosina quinasa para el tratamiento de rinosinusitis cronica.
CA2601936C (en) 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
CN101351563A (zh) 2005-10-05 2009-01-21 阿斯利康(英国)有限公司 用于预测或监测病人对于ErbB受体药物的响应的方法
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US9738935B2 (en) 2011-11-10 2017-08-22 Roche Molecular Systems, Inc. Complex mutations in the epidermal growth factor receptor kinase domain
EP3603678A3 (en) * 2011-12-14 2020-07-29 The Board of Regents of the University of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
AU2013355260B2 (en) 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
US20180057603A1 (en) 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
TWI603971B (zh) 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
EP3699589A1 (en) 2014-12-12 2020-08-26 Celcuity Inc. Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
CN107530434A (zh) 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
US10308658B2 (en) 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
EP3458064A1 (en) 2016-05-18 2019-03-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
WO2018213770A1 (en) 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
CA3076915A1 (en) 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
KR20190054826A (ko) 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
JP7386174B2 (ja) 2018-03-27 2023-11-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US20210235688A1 (en) 2018-04-19 2021-08-05 Board Of Regents, The University Of Texas System Methods for measuring and stabilizing stat3 inhibitors
SG11202012064PA (en) 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
CA3098204A1 (en) 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
KR20210066819A (ko) 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
KR20210107023A (ko) * 2018-12-21 2021-08-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 조합 요법
WO2020150208A1 (en) 2019-01-14 2020-07-23 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
US12679855B2 (en) 2019-01-27 2026-07-14 Board Of Regents, The University Of Texas System Inhibitors of the enzyme enolase for precision oncology
WO2020172485A1 (en) 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Methods of using imipridones
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US20200299783A1 (en) 2019-03-18 2020-09-24 Board Of Regents, The University Of Texas System Molecular signature for selecting lymphoma patients for treatment with ibrutinib
WO2020198633A1 (en) 2019-03-27 2020-10-01 Board Of Regents, The University Of Texas System Nuclear-derived exosomes and methods of use thereof
WO2020205646A2 (en) 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Small molecule parg inhibitors and methods of use thereof
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
US20220143023A1 (en) 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
JP7709384B2 (ja) 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
JP7822597B2 (ja) 2019-04-17 2026-03-03 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物
KR102477643B1 (ko) * 2019-05-09 2022-12-13 주식회사 엘지에너지솔루션 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
WO2020251965A1 (en) 2019-06-10 2020-12-17 Board Of Regents, The University Of Texas System Combinatorial therapy targeting parp1 and rtk
US20220356467A1 (en) 2019-06-25 2022-11-10 Board Of Regents, The University Of Texas System Methods for duplex sequencing of cell-free dna and applications thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516082A (ja) 2011-06-07 2014-07-07 ハンミ ファーム. シーオー., エルティーディー. ガン細胞の増殖を阻害するアミド誘導体および非金属塩滑沢剤を含む医薬組成物
WO2017210214A1 (en) 2016-05-31 2017-12-07 Pierian Holdings, Inc. Methods of drug therapy selection for breast cancer patients based on her2 and her3 pathway subtyping

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ariella B. HANKER et al.,"An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer",Cancer Discovery,2017年,Vol.7,No.6,p.575-585,DOI: 10.1158/2159-8290.CD-16-1431
Jacqulyne P. Robichaux et al.,"Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer",Nature Medicine,2018年,Vol.24,No.5,p.638-646,DOI: 10.1038/s41591-018-0007-9
Mi Young Cha et al.,"Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer models",International Journal of Cancer,2012年,Vol.130,p.2445-2454,DOI: 10.1002/IJC.26276
Runjun D. KUMAR et al.,"Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types",Scientific Reports,2017年,Vol.7: 6418,p.1-12,DOI: 10.1038/s41598-017-06366-x
Takamasa KOGA et al.,"Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study",Lung Cancer,2018年,Vol.126,p.72-79,DOI: 10.1016/j.lungcan.2018.10.019
Wenhsiang Wen et al.,"Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers",The Journal of Molecular Diagnostics,2015年09月,Vol.17,No.5,p.487-495,DOI: 10.1016/j.jmoldx.2015.04.003

Also Published As

Publication number Publication date
KR20210145161A (ko) 2021-12-01
WO2020205632A1 (en) 2020-10-08
US20220175778A1 (en) 2022-06-09
PH12021552110A1 (en) 2022-06-06
CN113766955A (zh) 2021-12-07
WO2020205632A8 (en) 2021-10-14
AU2020256119A1 (en) 2021-10-07
US12629375B2 (en) 2026-05-19
EP3946632A1 (en) 2022-02-09
IL286576A (en) 2021-12-01
JP2022527499A (ja) 2022-06-02
EP3946632A4 (en) 2023-01-04
MX2021011925A (es) 2021-11-03
BR112021019376A2 (pt) 2021-12-07
SG11202109531UA (en) 2021-09-29
CA3132834A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
JP7685550B2 (ja) Egfrまたはher2のエクソン20変異を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7650814B2 (ja) Egfrまたはher2エクソン20挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
JP7709384B2 (ja) チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
JP7822597B2 (ja) チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US12629375B2 (en) Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
WO2020030977A2 (en) Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors
JP7564806B2 (ja) がんの処置のための併用療法
JP2021519306A (ja) Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
HK40064724A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
HK40066138A (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
EA041212B1 (ru) Соединения с противоопухолевой активностью в отношении раковых клеток, несущих мутации в 20 экзоне egfr или her2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230322

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250618

R150 Certificate of patent or registration of utility model

Ref document number: 7700043

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150